Asymptomatic Mild-to-Moderate Carotid Stenosis (Investigational Adjunct)
Investigational adjunct for asymptomatic mild-to-moderate carotid stenosis; risk-factor management (statin, antiplatelet, blood pressure, smoking cessation, glycemic control) remains evidence-based; symptomatic or high-grade disease requires vascular surgery referral.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for carotid stenosis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational, with no efficacy or safety data in this population, and direct cervical placement is contraindicated.
- What evidence exists?
- Tier C (investigational). There are no controlled trials. The only clinical report identified is a small uncontrolled Russian series of 33 people, many with more advanced or symptomatic disease, that tracked cholesterol, clotting and mood measures rather than plaque or stroke. Evidence-based management of asymptomatic 50 to 69 percent carotid stenosis is aggressive risk-factor optimization: high-intensity statin, antiplatelet therapy, blood pressure under 140/90, smoking cessation, glycemic control if diabetic, and lifestyle modification. Carotid endarterectomy or stenting is reserved for symptomatic disease or asymptomatic stenosis over 80 percent in selected low-perioperative-risk patients. Duplex ultrasound surveillance is standard.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Local bruising and tenderness for 5 to 10 days
- Aeromonas hydrophila infection (rare)
- Allergic reaction to leech saliva (uncommon)
- Failure to address the disease itself — no stroke risk reduction is expected from this therapy
- Delay of evidence-based risk-factor management (statin, antiplatelet, blood pressure, smoking cessation, glycemic control)
- Bleeding risk if concurrent antiplatelet therapy is active
- Hypothetical but real risk if a practitioner places a leech in the anterior cervical triangle near the carotid artery (this is absolutely contraindicated)
- Who should not consider this
- Anyone with symptoms of TIA or stroke (urgent vascular evaluation)
- Patients with high-grade stenosis over 80 percent (vascular surgery referral)
- Patients on anticoagulants (aspirin and clopidogrel, alone or together, are not a contraindication by themselves: tell your doctor, who starts with fewer leeches)
- Patients who have had carotid endarterectomy or stenting
- Patients with bleeding disorders or anemia
- Anyone offered direct cervical placement (this is absolutely contraindicated; only trapezius or upper shoulder is acceptable)
- What to ask your clinician
- What is the current stenosis percentage on duplex ultrasound, and is it mild, moderate, or severe?
- Am I on a high-intensity statin, antiplatelet therapy, and have I optimized blood pressure, glycemic control, and tobacco use?
- Do I need vascular surgery referral now or surveillance only?
- Where exactly will the leech be placed — confirm it is NOT in the anterior neck near the carotid?
- What is the practitioner's experience with this indication?
- Is there any plausible mechanism that would benefit my stenosis itself?
- When to seek urgent care
- Sudden weakness or numbness of face, arm, or leg, especially on one side
- Sudden trouble speaking, understanding speech, or vision loss
- Sudden severe headache, dizziness, or loss of balance
- Brief or transient version of any of the above (possible TIA)
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, or pus around any bite site, or fever above 38.0 C / 100.4 F
What this does NOT mean
- Leeches are never placed near the carotid arteries themselves — the only acceptable site is trapezius or upper shoulder skin, far from the cervical vessels.
- It does not reduce stroke risk and does not substitute for statin, antiplatelet, blood-pressure, glycemic, or smoking-cessation therapy.
- Symptomatic disease (TIA, stroke) or high-grade stenosis requires immediate vascular surgery referral, not investigational adjuncts.
- No controlled trial was identified, and the one small uncontrolled series found did not report results separately for people with asymptomatic mild-to-moderate stenosis or assess plaque; there are no efficacy or safety data in this population.
Safety cross-references
Clinical Profile
- Category
- Vascular
- ICD-10
- I65.21, I65.22, I65.23, I65.29
- Safety tier
- High
Evidence Summary
Asymptomatic carotid stenosis of 50-69 percent is managed by aggressive risk-factor optimization (high-intensity statin, antiplatelet therapy, blood pressure control under 140/90, smoking cessation, glycemic control in diabetes, lifestyle modification). Carotid endarterectomy or stenting is reserved for symptomatic disease or asymptomatic stenosis >80 percent in selected low-perioperative-risk patients. Duplex ultrasound surveillance is standard. No controlled trial of hirudotherapy in carotid atherosclerosis was identified in PubMed, Europe PMC, ClinicalTrials.gov or the Baskova and Isakhanyan 2004 monograph, and none in asymptomatic mild-to-moderate stenosis. The closest clinical report is an uncontrolled Russian series (Pospelova, 2010) of 33 patients with atherosclerotic stenoses or occlusions of neck and brain arteries, 18 of whom had already had a stroke. It reported lower total and LDL cholesterol (23 patients not taking lipid-lowering drugs), normalized fibrinogen in 9 patients with raised levels, better vasomotor reactivity in 11 patients with reduced reactivity, and lower anxiety and depression scores. It had no control group, reported no change in plaque or stenosis, and recorded 2 TIAs and 1 recurrent stroke among 23 patients followed for 3 to 7 years, so it cannot show stroke risk reduction. Mechanistic rationale would invoke anticoagulant and anti-inflammatory effects of leech saliva, but no human evidence supports plaque stabilization or stroke risk reduction, and direct cervical placement is high-risk for arterial proximity, vagal effects, and inadvertent injury to the carotid bulb.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Neither book writes about carotid artery stenosis; Baskova and Isakhanyan speak of atherosclerosis in general and of atherosclerosis of cerebral vessels and include atherosclerosis in the list of indications for hirudotherapy, while Michalsen et al. speak of peripheral arterial occlusive disease (obliterative disease of the leg arteries) as a manifestation of atherosclerosis[B1][B3].
- Baskova and Isakhanyan gathered observations of blood lipids, mainly in patients with atherosclerosis of the vessels of the heart and brain, and write that after hirudotherapy, according to these observations, cholesterol and low-density lipoproteins fell, but they themselves note that these observations are not enough to judge a marked anti-atherosclerotic effect[B1].
- These observations concerned blood tests, not the size of plaques or the narrowing of arteries; changes in the vascular wall or the risk of stroke were not measured in them[B1].
- On peripheral atherosclerosis of the leg arteries, Michalsen et al. write that leeches are unlikely to produce significant improvement of the vascular lesions themselves, and that the transient effects on the viscosity and flow of the blood appear minor compared with established drug treatments[B3].
- In the chapter on legal aspects, Michalsen et al. write that specific risks must be explained to the patient in advance, especially if leeches are applied to critical sites of the face or neck; Flecken and Michalsen, in the chapter on contraindications, recommend written informed consent[B3].
- Baskova and Isakhanyan name taking anticoagulants as a contraindication; Flecken and Michalsen name taking warfarin, heparin and other anticoagulants as an absolute contraindication, and do not regard aspirin and clopidogrel as contraindications in themselves: fewer leeches are used in the first session and the patient is asked about bleeding tendencies[B1][B3].
- Michalsen et al. remind readers that leeches themselves lower blood pressure, and describe two patients on triple antihypertensive therapy who had a brief fainting episode a few hours after leeches[B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active deep vein thrombosis (acute phase)
- Critical limb ischemia (ABI <0.4)
- Symptomatic carotid disease (TIA, stroke) — refer vascular surgery
- High-grade stenosis (>80 percent) — refer vascular surgery
- Direct cervical or carotid-region placement (absolute)
- Prior carotid endarterectomy or stenting
Related Conditions
Peripheral Artery Disease (Claudication, Investigational)
Highly investigational adjunct for intermittent claudication; ABI must be assessed first; critical limb ischemia is an absolute contraindication.
Essential Hypertension (Adjunctive)
Investigational adjunctive use with only non-randomized clinical reports identified; proposed mechanisms are blood-volume removal and hirudin effects on vessels; not a substitute for pharmacotherapy.
Atrial Fibrillation (Adjunctive Investigational)
Highly investigational adjunct for paroxysmal atrial fibrillation; no controlled trials; conventional anticoagulation and rate/rhythm control remain primary.
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label adjunct to compression; the journal evidence is one small open-label randomized trial in varicose veins (n=50) and a 20-patient uncontrolled series; the books describe further reports (see “What the books describe” below).
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.